Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative.
about
EXAMINING EVIDENCE IN U.S. PAYER COVERAGE POLICIES FOR MULTI-GENE PANELS AND SEQUENCING TESTS.Genetic testing in steroid-resistant nephrotic syndrome: why, who, when and how?Genetic Testing in a Population-Based Sample of Breast and Ovarian Cancer Survivors from the REACH Randomized Trial: Cost Barriers and Moderators of Counseling Mode.Insurance coverage for genomic tests.Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning?
P2860
Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative.
description
2017 nî lūn-bûn
@nan
2017 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Payer Coverage for Hereditary ...... Precision Medicine Initiative.
@ast
Payer Coverage for Hereditary ...... Precision Medicine Initiative.
@en
type
label
Payer Coverage for Hereditary ...... Precision Medicine Initiative.
@ast
Payer Coverage for Hereditary ...... Precision Medicine Initiative.
@en
prefLabel
Payer Coverage for Hereditary ...... Precision Medicine Initiative.
@ast
Payer Coverage for Hereditary ...... Precision Medicine Initiative.
@en
P2093
P2860
P356
P1476
Payer Coverage for Hereditary ...... Precision Medicine Initiative.
@en
P2093
Allison W Kurian
Christine B Weldon
Julia R Trosman
Kathryn A Phillips
Michael P Douglas
Patricia A Deverka
R Kate Kelley
P2860
P304
P356
10.6004/JNCCN.2017.0022
P577
2017-02-10T00:00:00Z